pioneering technology, preserving life.

We’re addressing a vital global need.

Every year, thousands of people suffer due to the lack of available healthcare treatments. Cryopreservation is a process that preserves biomaterials for future use by cooling the samples to very low temperatures.

Cryopreservation can improve the availability, quality and consistency of biomaterials, including for life-saving therapeutic treatments globally.

Historically, cryopreservation processes, such as freezing and thawing, caused high levels of cellular damage to biomaterials which resulted in low quality outcomes, increased processing costs and the inability to cryopreserve some biomaterials at all.

We founded Vitrafy to improve the quality of healthcare treatments by providing effective cryopreservation solutions via its platform technology solution. Preserving life.

The world’s demand for high quality healthcare products is only increasing. Improving cryopreservation sample outcomes is a vital need that can ensure constant supplies of high quality, life-saving and life-improving products are available.

Brent Owens, Vitrafy Co-founder.

We're improving cell survival, becoming the quality standard.

Our premise is simple:  less cellular damage; results in less waste; that increases availability of higher quality treatments; at a lower cost.

The Vitrafy Solution.

At Vitrafy, we have developed a range of proprietary smart cryopreservation hardware devices and Lifechain™, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution, to retain the quality of cryopreserved biomaterials.


The Lifechain™ software platform combines the most advanced software functions, such as AI, machine learning and IoMT integration, to ensure supply chain processes are controlled, traced, tracked and monitored, to the highest quality standards, in a safe and secure way. A complete chain of custody to retain the quality of precious biomaterials.

Smart Devices

Vitrafy has developed a suite of proprietary smart devices that are portable, efficient, and safe. These include Vitrafy’s Smart Cryopreservation Device; Vitrafy’s Smart Thawing Device and Vitrafy’s Smart Packaging.

Our solutions are tailored to individual cell lines.

The novelty of our innovative technology solution includes the ability to tailor cryopreservation processes to the individual cell line, whether it is human blood platelets that will be used for emergency trauma response or specific animal genetics to improve sustainable breeding and farming outcomes. The result? New cryopreservation quality standards.

Benefits of Vitrafy’s patented supply chain solution:

Vitrafy out in the world.

We are collaborating with global industry leaders to apply Vitrafy’s cryopreservation solution to address real world problems, from critical blood supplies to precious CAR T-Cells for revolutionary cancer treatments. These areas, as well as many others, depend on cryopreservation to operate. But existing quality and consistency of outcomes are heavily impacted. Until now.

Blood Platelets

Blood platelets are small components of your blood that help with clotting. Your body’s natural bandage to stop bleeding, they are critical to life. Platelets have a shelf life of up to seven days, after which the components are discarded if they have not been transfused. Cryopreservation can be a viable solution to increasing supply shortages and mitigating large amounts of waste. Unfortunately, existing processing methods result in post thaw outcomes that make it unfeasible – the regulatory compliance standard is only 50% post thaw recovery.

To meet the global need for emergency platelet supply, a better cryopreservation solution is needed. Vitrafy has completed a two-phase, third party lab testing study with a leading national blood service provider with the aim of improving the quality and recovery rates of cryopreserved blood platelets. 

Results include:

Phase One   97.5%

Platelet recovery

Phase Two   Functionality

Phase Two   Functionality

of the cells is retained

Cell and Gene Therapy (CGT)

Access and availability of CGT treatments (e.g. CAR T-Cell therapy) currently have many barriers and limitations. These complex supply chains, which often include multiple cryopreservation steps result in high levels of cellular damage. For these revolutionary treatments to be made available for patients at scale, major hurdles need to be overcome. There’s an urgent need for improvement and standardisation.

Vitrafy collaborated with a large American blood processing and biomanufacturing organisation and completed a phase 1 non-clinical study on T-Cells, for the application of CAR-T Cell therapy.

Phase 1 T-Cell testing has been completed showing that post thaw viability of Vitrafy cryopreserved T-Cells are comparable to fresh – a huge leap forward and a major step towards setting new quality standards:

Fresh T-Cells     95%


Vitrafy post
thaw T-Cells     94%


Aquaculture breeding programs

Animal breeding programs, such as Aquaculture and Bovine, are crucial and can positively impact environmental sustainability and operational efficiency, both now and increasingly in the future. They are essential processes that can also mitigate areas that contribute to climate change, impact biodiversity, and food security. 

Cryopreservation is a vital process in animal breeding programs. Existing cryopreservation processes of animal sperm, such as fish sperm, have very low post thaw quality outcomes which can result in extremely low fertilisation rates. Vitrafy partnered with a large salmon producer to rectify this and improve the quality of their cryopreserved fish sperm, that should subsequently increase overall fertilisation outcomes as part of the breeding program.

Using our cryopreservation solution, post thaw fish sperm quality was maintained at the highest quality, resulting in the greatest fertilisation outcomes the company had ever achieved since its breeding program started.

0-40%    Regular cryopreserved fertilisation rates

76%     Fresh fertilisation rates

72%     Vitrafy 2024 fertilisation rates

This process is applicable to other species, such as bovine and equine, as well as a very similar process in human sperm cryopreservation.

Stay Tuned